Publications by authors named "Sinem Burcu Kocaer"
Article Synopsis
- * Researchers analyzed data from 330 patients diagnosed with GCA, finding that 18.8% experienced relapses during a follow-up period, and only 23.8% were able to stop GC treatment entirely.
- * The study highlighted that a significant portion of patients (66.2%) had at least one indication of damage due to vasculitis, and there were also considerable side effects related to GC treatment.
Background: Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as caus- ing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix.
View Article and Find Full Text PDFIntroduction: We aimed to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the course and treatment of patients with inflammatory rheumatic musculoskeletal disease (iRMD) using biologic or targeted synthetic disease modifying and rheumatic drugs (b/tsDMARDs).
Methodology: The study was carried out in two stages: in the first stage we investigated the delay of b/tsDMARD treatment in the first 3 months of the pandemic; in the second stage, we investigated all patients who decided to continue treatment after interruption in the 12-month period.
Results: A total of 521 patients were included in the study.
Objectives: Vogt-Koyanagi-Harada Disease (VKHD) is a systemic autoimmune disorder characterized by granulomatous panuveitis. Inflammatory rheumatic diseases (IRDs) are among the differential diagnosis of VKHD. However, current knowledge on the rheumatological aspects of VKHD is still limited.
View Article and Find Full Text PDFBackground: This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients.
Methods: This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre-d (before disease onset) and post-d (after disease onset).
Article Synopsis
- The study aimed to compare the effectiveness and safety of TNF inhibitors and tocilizumab (TCZ) in treating Takayasu arteritis in patients who didn't respond to standard immunosuppressive drugs.
- A total of 111 patients participated, receiving various biologic treatments, with similar remission rates and glucocorticoid (GC) reduction between the two treatment groups after follow-up.
- The findings indicate that both TNF inhibitors and TCZ have comparable drug survival rates and outcomes in managing Takayasu arteritis, suggesting that either option is viable for treatment.